Taro Pharmaceuticals

MediWound Reports Second Quarter 2023 Financial Results and Provides Company Update

Retrieved on: 
Tuesday, August 15, 2023
GMP, Data management, Operating cost, Chairperson, Table, VLU, Event, Conference call, Bank statement, Eastern Time Zone, Bromelain (pharmacology), Tax, European Directive on Traditional Herbal Medicinal Products, BCC Lions F.C., Strata Skin Sciences, Research, HERE, Trial of the century, Forecasting, EMA, Committee, European Medicines Agency, Taro Pharmaceuticals, EBITDA, Patient, Sun Pharma, NEXT, Depreciation, Mouth ulcer, Growth, Committee for Medicinal Products for Human Use, Phase, FDA, Carcinoma, Regulation of tobacco by the U.S. Food and Drug Administration, BARDA, BCC, Adjustment, Food, Conference, CHMP, Pharmaceutical industry, Rare-earth element, Medical device, Video game, Bookkeeping, Insurance, Vericel

YAVNE, Israel, Aug. 15, 2023 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair, today announced financial results for the second quarter ended June 30, 2023, and provided a corporate update.

Key Points: 
  • Second Quarter 2023 Highlights and Recent Developments:
    Shipped NexoBrid finished product to Vericel for the U.S. commercial launch in June 2023.
  • Revenues: Revenues for the second quarter 2023 were $4.8 million, compared to $4.7 million in the second quarter of 2022.
  • Research and development expenses in the second quarter 2023 were $2.0 million compared to $2.2 million in the second quarter of 2022.
  • Operating Results: Operating loss in the second quarter of 2023 was $4.0 million, compared to a $3.7 million loss in the second quarter of 2022.

CinCor Pharma Appoints Michael W. Kalb, Executive Vice President and Chief Financial Officer

Retrieved on: 
Monday, November 7, 2022
CFO, American Heart Association, Disclosure, Company, Accounting, American College of Cardiology, Therapy, Amarin Corporation, Primary aldosteronism, Kidney disease, Time, American College, Cardiology, Risk, Degenerative disease, Certified Public Accountant, GLOBE, Hypertension, Population, Adult, Taro Pharmaceuticals, Ernst, Ernst & Young, COVID-19, LLP, Stroke, CKD, Death, Annual report, U.S. Securities and Exchange Commission, Aldosterone, Retirement, Security (finance), SEC, Achievement, Patient, Management, Pharmaceutical industry, Collection

WALTHAM, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (CinCor) announced the appointment of Michael W. Kalb as Executive Vice President and Chief Financial Officer (CFO), effective November 4.

Key Points: 
  • WALTHAM, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (CinCor) announced the appointment of Michael W. Kalb as Executive Vice President and Chief Financial Officer (CFO), effective November 4.
  • He is replacing Terry Coelho who is retiring from her role as Executive Vice President, CFO and Chief Business Development Officer.
  • Mr. Kalbs experience includes six years as Chief Financial Officer for Amarin Corporation, a publicly traded, multinational cardiovascular focused pharmaceutical company.
  • Prior to Amarin, he worked for seven years at Taro Pharmaceuticals where he was the Chief Financial Officer and Chief Accounting Officer.

Ukrainian American Doctors Send $35 Million Dollars Worth of Lifesaving Medications to Be Distributed to Desperate Ukrainian Hospitals

Retrieved on: 
Friday, June 3, 2022
World News Connection, Friends, Mark (given name), Shimon Shteynberg, Ambulance, State University of New York Upstate Medical University, Organization, Patient, Taro Pharmaceuticals, Hospital, Degenerative disease, Full, Medical device, Urology

EAST RUTHERFORD, N.J., June 3, 2022 /PRNewswire/ -- On Thursday, June 2nd, a chartered flight containing donated medical supplies with a retail value of over $35 million left the United States for Poland, where the supplies will then be distributed to hospitals across Ukraine. Organized by two Ukrainian doctors, Gennady Bratslavsky and Alex Golubenko, childhood best friends from Kyiv who live and work in New York, the plane is filled with life saving medications including antibiotics, anti seizure, antifungal, and other medications. This generous donation was facilitated by Elena Novikova, provided by Taro Pharmaceuticals, organized by Charita Shteynberg (founder of World of Connections, a liaison service for nonprofit organizations that acquired much of the supplies from hospitals and nonprofits), and accepted under Dr. Bratslavsky's medical license.

Key Points: 
  • Organized by two Ukrainian doctors, Gennady Bratslavsky and Alex Golubenko, childhood best friends from Kyiv who live and work in New York, the plane is filled with life saving medications including antibiotics, anti seizure, antifungal, and other medications.
  • As soon as Dr. Bratslavsky and Dr. Golubenko saw their native country attacked, they sprang into action, founding Help Free Ukraine , an organization which has raised hundreds of thousands of dollars that contributed to purchasing these medications.
  • Additionally, Dr. Bratslavsky and Alex purchased gas masks, satellite phones, ambulances, and individual first aid kits for first responders and Ukrainian hospitals.
  • Mr. Khan also works closely with Sebastian Kopolovich and Anna Popruga, who have provided enormous logistical support for this operation.

Schrocken Strengthens the Executive Team and Board as It Gears up for US Launch and Raise Series A Funding Round

Retrieved on: 
Thursday, March 24, 2022
Technology, Finance, Professional Services, Software, Biotechnology, Internet, Pharmaceutical, Health, Science, Other Science, Cloud, Progress Software, VIC, Trust, COO, Sale, Data management, College, Inc., University, Technology transfer, Board, NYSE, Software as a service, Taro Pharmaceuticals, CEO, Software, Board of directors, Industry, Technology, Waters Corporation, SAP, Director, Sybase iAnywhere, Analytics, Solution, Bernie, Holy Cross, Monotype Imaging, Management, Agfa-Gevaert, Technology, Finance, Professional Services, Software, Biotechnology, Internet, Pharmaceutical, Health, Science, Other Science

An experienced business leader and startup executive, Prusaczyk succeeded Yogendra Chordia and assumed responsibilities on March 21, 2022.

Key Points: 
  • An experienced business leader and startup executive, Prusaczyk succeeded Yogendra Chordia and assumed responsibilities on March 21, 2022.
  • He has thirty years of leadership experience across various industries; ranging across software, life sciences data management, business intelligence, and medical devices.
  • His experience includes serving on the management team of NuGenesis Technologies, a life sciences data management platform.
  • He is the Chief Executive Officer and a Board member of Taro Pharmaceuticals, a NYSE listed multinational pharmaceutical company.

Taro Provides Results for Quarter Ended June 30, 2021

Retrieved on: 
Wednesday, July 28, 2021
Biotechnology, FDA, Pharmaceutical, Health, Plants, Food and drink, Agriculture, Science and technology in Israel, Taro Pharmaceuticals, Taro, New York Stock Exchange

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (Taro) today provided unaudited financial results for the quarter ended June 30, 2021.

Key Points: 
  • Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (Taro) today provided unaudited financial results for the quarter ended June 30, 2021.
  • Quarter ended June 30, 2021 Highlights - compared to Quarter ended June 30, 2020
    Net sales increased $29.5 million, or 25.1%, to $147.1 million.
  • Foreign Exchange expense of $0.3 million compared to income of $0.2 million in the comparable quarter an unfavorable impact of $0.5 million.
  • On June 17, 2021, Taro filed its Annual Report on Form 20-F with the U.S. Securities and Exchange Commission (SEC) for the fiscal year ended March 31, 2021.

Taro to Announce First Quarter Results on July 27, 2021

Retrieved on: 
Wednesday, July 21, 2021
Health, Pharmaceutical, Science and technology in Israel, Taro Pharmaceuticals, Pharmaceutical industry, Health care, Life sciences

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) announced today that it plans to release its financial results for the quarter ended June 30, 2021, after the close of market on Tuesday, July 27, 2021.

Key Points: 
  • Taro Pharmaceutical Industries Ltd. (NYSE: TARO) announced today that it plans to release its financial results for the quarter ended June 30, 2021, after the close of market on Tuesday, July 27, 2021.
  • Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing of the highest quality healthcare products.
  • For further information on Taro Pharmaceutical Industries Ltd., please visit the Companys website at www.taro.com .
  • View source version on businesswire.com: https://www.businesswire.com/news/home/20210720006288/en/

Taro Announces Resignation of Chief Financial Officer

Retrieved on: 
Wednesday, July 14, 2021
Biotechnology, General Health, Pharmaceutical, Health, Science and technology in Israel, Taro Pharmaceuticals, Health sciences, Pharmaceutical industry, Pharmaceutical sciences, Health care

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (Taro or the Company) announced today that it has accepted the resignation of its Chief Financial Officer, Daphne Huang, effective August 6, 2021.

Key Points: 
  • Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (Taro or the Company) announced today that it has accepted the resignation of its Chief Financial Officer, Daphne Huang, effective August 6, 2021.
  • The Company has initiated a search for a successor as Chief Financial Officer.
  • Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing of the highest quality healthcare products.
  • For further information on Taro Pharmaceutical Industries Ltd., please visit the Companys website at www.taro.com .

Taro Annual Report on Form 20-F Available For Fiscal Year Ended March 31, 2021

Retrieved on: 
Friday, June 18, 2021
Pharmaceutical, Professional services, Health, Finance, Health sciences, Science and technology in Israel, Taro Pharmaceuticals, Pharmaceutical industry, Health care, Health

Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing of the highest quality healthcare products.

Key Points: 
  • Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing of the highest quality healthcare products.
  • For further information on Taro Pharmaceutical Industries Ltd., please visit Taros website at www.taro.com .
  • View source version on businesswire.com: https://www.businesswire.com/news/home/20210618005039/en/

Taro to Announce Full Year Results on May 19, 2021

Retrieved on: 
Wednesday, May 12, 2021
Health, Pharmaceutical, Health sciences, Science and technology in Israel, Taro Pharmaceuticals, Pharmaceutical industry, Health care, Health

b'Taro Pharmaceutical Industries Ltd. (NYSE:TARO) announced today that it plans to release its financial results for year ended March 31, 2021, on Wednesday, May 19, 2021.\nTaro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing of the highest quality healthcare products.

Key Points: 
  • b'Taro Pharmaceutical Industries Ltd. (NYSE:TARO) announced today that it plans to release its financial results for year ended March 31, 2021, on Wednesday, May 19, 2021.\nTaro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing of the highest quality healthcare products.
  • For further information on Taro Pharmaceutical Industries Ltd., please visit the Company\xe2\x80\x99s website at www.taro.com .\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210512006053/en/\n'

Taro Provides Results for December 31, 2020

Retrieved on: 
Wednesday, January 27, 2021
Health, Pharmaceutical, Asset, Cash, Cash and cash equivalents, New York Stock Exchange, Taro Pharmaceuticals, Economy, New York City

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (Taro or the Company) today provided unaudited financial results for the quarter and nine months ended December 31, 2020.

Key Points: 
  • Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (Taro or the Company) today provided unaudited financial results for the quarter and nine months ended December 31, 2020.
  • Quarter ended December 31, 2020 Highlights compared to December 31, 2019
    Net sales of $140.1 million decreased $7.5 million.
  • Nine Months ended December 31, 2020 Highlights compared to December 31, 2019
    Net sales of $400.6 million decreased $69.2 million.
  • As of December 31, 2020, cash and cash equivalents and marketable securities (both short and long-term) of $1.55 billion decreased $18.2 million from March 31, 2020.